
CORPORATE FACT SHEET




Corporate Profile:

IntriCon Corporation (NASDAQ: IIN), a medical device company based in Arden Hills, MN, is committed to enhancing the mobility and effectiveness of body-worn devices that connect people to people and to devices around them. IntriCon serves the body-worn device market by designing, developing, engineering, distributing, and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies and complete assemblies, primarily for medical bio-telemetry devices, value hearing health, professional audio communication devices. Over the past several years, IntriCon has increased investments in the continued development of four critical core technologies: Ultra-Low-Power Digital Signal Processing, Ultra-Low-Power Wireless, Microminiaturization, and Miniature Transducers. These four core technologies serve as the foundation of current and future product platform development, designed to meet the rising demand for smaller, portable more advanced devices. IntriCon is focused on three key markets: medical, value based hearing healthcare, and professional audio communications. Utilizing this expertise IntriCon is moving to: improve margins by actively increasing the percentage of proprietary content; increase core business revenue and margins by maximizing product research and development; strengthen its leadership position in the bodyworn device market by pursuing merger and acquisition opportunities. More information about the company and its products can be found at www.intricon.com.

Revenue & EPS (continuing operation) Quarterly Trends



TTM Revenue by Market from continuing operations



Stock Performance:

IIN (Common Stock)	
Exchange	NASDAQ GM (US Dollar)
Price	\$26.38
Volume Change	1%
Volume	147,300
52 Week Range	\$16.70 - \$76.80
Market Cap	\$228,555
EPS from Continuing Rolling Operations \$0.64	
PE Ratio	41
Shares Outstanding	8,663,946

Data as of 12/31/2018



For more up-to-date stock performance information, visit the Investor Relations section on www.IntriCon.com

INVESTOR CONTACT: SCOTT LONGVAL



Recent Events:

August 20, 2018

The Company completed a public offering of 1,725,000 shares of its common stock. All shares in the offering were sold by the Company at a price to the public of \$55.00 per share. Net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, and board and management stock repurchases, totaled more than \$63.0 million. The company used a portion of these proceeds to pay off bank debt and invested the remainder in short-term investment securities.

Financial Update:

February 19, 2019

For the 2018 fourth quarter, the company reported net revenue of \$30.8 million, up 41.1 percent from \$21.8 million in the comparable prior-year period. The increase was primarily due to year-over-year revenue gains from the company's largest medical customer and growth in its value-based indirect-to-end-consumer hearing healthcare business. Fourth-quarter gross margins were 30.0 percent, consistent with 30.0 percent in the prior-year fourth quarter. Gross margins in the quarter were constrained by costs related to additional infrastructure investments. Operating expenses for the fourth quarter were \$8.2 million, compared to \$6.1 million in the comparable prior-year period. The increase stemmed from increased advertising investments at Hearing Help Express (HHE), and support costs related to key initiatives to drive overall business growth. The company posted net income of \$868,000, or \$0.09 per diluted share, versus \$396,000 or \$0.05 per diluted share, for the 2017 fourth quarter.

Corporate Governance:

Mark S. Gorder
J. Scott Longval
Mike Geraci
Dennis Gonsior
Greg Gruenhagen

President, CEO & Founder CFO, Secretary & Treasurer VP, Sales & Marketing VP, Global Operations VP, Quality & Regulatory Affairs

Corporate Headquarters:

IntriCon Corporation 1260 Red Fox Road Arden Hills, MN 55112 Tel: 651.636.9770 Fax: 651.636.9503 www.IntriCon.com